Aurora Spine Corporation: First Surgical Implant of ZIP ULTRA(TM) MIS Interspinous Device Performed in the United Kingdom
19 Febrero 2014 - 8:01AM
Marketwired
Aurora Spine Corporation: First Surgical Implant of ZIP ULTRA(TM)
MIS Interspinous Device Performed in the United Kingdom
CARLSBAD, CALIFORNIA--(Marketwired - Feb 19, 2014) - Aurora
Spine Corporation (TSX-VENTURE:ASG) announced today the first
surgical implant of the company's ZIP ULTRA™ Minimally Invasive
Interspinous Device in the United Kingdom. The surgery was
performed at the University Hospital Llandough, a part of the
Cardiff and Vale University Health Board, by Mr. Stuart James.
"The ZIP MIS implant is very well designed. It is both stable
and secure. Implanting the device was simple, easy and safe," said
Mr. Stuart James. "I will be expanding my use of the product as I
believe it has multiple spine fusion indications."
Mr. James has completed a recognized spine fellowship in
Bristol, UK, where he has gained extensive experience in all
aspects of spinal disease and spinal conditions. His experience
ranges from trauma and tumor work through to adult and pediatric
complex deformity of the spine. In addition to his spine specialist
training in the UK, Mr. James has gained further exposure and
training in cutting edge contemporary spinal techniques across
Europe and the USA.
"We are absolutely thrilled that Aurora now offers our MIS
portfolio in the United Kingdom, including the ZIP MIS Interspinous
System. We believe that the ZIP device will change spine surgery in
the U.S. with a true minimally invasive approach designed to
achieve reproducible, superior patient outcomes," said Trent
Northcutt, President and Chief Executive Officer. "We are eager to
introduce the ZIP across the U.K., and to drive the shift toward
minimally invasive techniques. Our initial reception in the UK has
been fantastic, and we want to thank Mr. James for his support of
the Aurora vision."
About Aurora Spine
Aurora Spine is an early stage company focused on bringing new
solutions to the spinal implant market through a series of
innovative, minimally invasive, regenerative spinal implant
technologies.
Forward-Looking Statements
This news release contains forward-looking information that
involves substantial known and unknown risks and uncertainties,
most of which are beyond the control of Aurora Spine, including,
without limitation, those listed under "Risk Factors" and
"Cautionary Statement Regarding Forward-Looking
Information" in Aurora Spine's final prospectus (collectively,
"forward-looking information"). Forward-looking information in this
news release includes information concerning the proposed use and
success of Aurora Spine's products in surgical procedures. Aurora
Spine cautions investors of its securities about important factors
that could cause Aurora Spine's actual results to differ materially
from those projected in any forward-looking statements included in
this news release. Any statements that express, or involve
discussions as to, expectations, beliefs, plans, objectives,
assumptions or future events or performance are not historical
facts and may be forward-looking and may involve estimates,
assumptions and uncertainties which could cause actual results or
outcomes to differ unilaterally from those expressed in such
forward-looking statements. No assurance can be given that the
expectations set out herein will prove to be correct and,
accordingly, prospective investors should not place undue reliance
on these forward looking statements. These statements speak only as
of the date of this press release and Aurora Spine does not assume
any obligation to update or revise them to reflect new events or
circumstances.
Aurora Spine CorporationTrent NorthcuttPresident and Chief
Executive Officer(760) 424-2004Aurora Spine CorporationEric
FronkChief Financial Officer(760) 424-2004www.auroraspine.us
Aurora Spine (TSXV:ASG)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Aurora Spine (TSXV:ASG)
Gráfica de Acción Histórica
De May 2023 a May 2024